李靖,王乐丰,徐琳,倪祝华,葛永贵,迟永辉

• 1:首都医科大学附属北京朝阳医院心脏中心

摘要(Abstract)：

目的探讨对于急诊经皮冠状动脉介入治疗(PCI)后的急性ST段抬高性心肌梗死(STEMI)患者,增加氯吡格雷的维持剂量能否进一步降低腺苷二磷酸(ADP)诱导的血小板聚集率以及高敏C反应蛋白(hs-CRP)浓度,并影响临床预后。方法入选患者为2008年4月至11月在北京朝阳医院心脏中心行急诊PCI的STEMI患者。所有患者在PCI前均服用氯吡格雷600mg以及阿司匹林300mg。将支架置入成功的患者随机分为氯吡格雷高维持剂量组与标准维持剂量组,分别给予氯吡格雷150mg/d及75mg/d维持,7d后两组均以标准剂量维持。分别于服用负荷剂量前及服药7d时测定患者的血小板聚集率以及hs-CRP浓度。1个月时随访,比较两组之间临床终点事件发生率。结果共有100例患者入选本研究,高维持剂量组与标准维持剂量组各50例。(1)两组的基本临床特征、基线水平ADP诱导的血小板聚集率和hs-CRP浓度之间的差异均无统计学意义。(2)服药7d时氯吡格雷高维持剂量组的血小板聚集率显著低于标准维持剂量组(40.29%±22.47%比50.42%±21.39%,P=0.023)。(3)服药7d时高维持剂量组的hs-CRP下降程度显著高于标准维持剂量组(1.65±1.06mg/L比1.00±0.79mg/L,P=0.001)。(4)血小板聚集率的下降程度与hs-CRP下降程度之间存在相关性(r=0.21,P=0.043)。(5)经1个月随访,两组中均无患者死亡或再发心肌梗死;标准维持剂量组发生1例支架内血栓,但两组差异无统计学意义(2%比0,P=0.317);两组均无大出血及小出血发生,高维持剂量组有2例患者发生不显性出血,标准维持剂量组有3例,但两组间差异无统计学意义(4%比6%,P=0.648)。结论增加氯吡格雷维持剂量可以显著降低患者血小板聚集率及hs-CRP浓度。未发现增加氯吡格雷维持剂量能显著改善患者短期预后。

关键词(KeyWords)： 心肌梗死;血小板聚集抑制剂;预后

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李靖,王乐丰,徐琳,倪祝华,葛永贵,迟永辉

参考文献(References)：

• [1]Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity.Circulation,2003,107:2908-2913.
• [2]Gurbel PA,Bliden KP,Hayes KM,et al.The relation of dosing to clopidogrel responsiveness and the incidence of high post-treat-ment platelet aggregation in patients undergoing coronary stent-ing.J Am Coll Cardiol,2005,45:1392-1396.
• [3]Heitzer T,Rudolph V,Schwedhelm E,et al.Clopidogrel im-poves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease.Arterioscler Thromb Vasc Biol,2006,26:1648-1652.
• [4]von Beckerath N,Kastrati A,Wieczorek A,et al.A double-blind randomized comparison between two different clopidogrel maintenance doses after percutaneous coronary intervention(ISAR-CHOICE2Trial)(abstr).Eur Heart J,2006,27:5039.
• [5]Angiolillo DJ,Shoemaker SB,Desai B,et al.Randomized com-parisonof a high clopidogrel maintenance dose in patients with di-abetes mellitus and coronary artery disease:results of the Optimi-zing Antiplatelet Therapy in Diabetes Mellitus(OPTIMUS)study.Circulation,2007,115:708-716.
• [6]Jeong YH,Lee SW,Choi BR,et al.Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity:Results of the ACCEL-RESISTANCE(Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Re-sistance)Randomized Study.J Am Coll Cardiol,2009,53:1101-1109.
• [7]Pearson TA,Mensah GA,Alexander RW,et al.Markers of in-flammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the A-merican Heart Association.Circulation,2003,107:499-511.
• [8]Lemesle G,Delhaye C,Sudre A,et al.Impact of high loading and maintenance dose of clopidogrel within the first15days after percutaneous coronary intervention on patient outcome.Am Heart J,2009,157:375-382.
• [9]Abuzahra M,Pillai M,Caldera A,et al.Comparison of Higher Clopidogrel Loading and Maintenance Dose to Standard Dose on Platelet Function and Outcomes After Percutaneous Coronary In-tervention Using Drug-Eluting Stents.Am J Cardiol,2008,102:401-403.
• [10]Craft RM,Chavez JJ,Snider CC,et al.Comparison of modified Thrombelastograph and Plateletworks whole blood assays to opti-cal platelet aggregation for monitoring reversal of clopidogrel inhi-bition in elective surgery patients.J Lab Clin Med,2005,145:309-315.
• [11]Agarwal S,Coakely M,Reddy K,et al.Quantifying the effect of antiplatelet therapy.Anesthesiology,2006,105:676-683.